Juan Carlos Núñez-Enríquez

Dr. Juan Carlos Núñez-Enríquez

Unidad de Investigación Médica en Epidemiología Clínica, Hospital de Pediatría CMN Siglo XXI, IMSS
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GCGabriela Marisol Cruz-Miranda
Gabriela Marisol Cruz-Miranda
AHAlfredo Hidalgo-Miranda
Alfredo Hidalgo-Miranda
DBDiego Bárcenas-López
Diego Bárcenas-López
Juan Carlos Núñez-EnríquezJuan Carlos Núñez-Enríquez
Juan Carlos Núñez-Enríquez
Julian Ramírez-BelloJulian Ramírez-Bello
Julian Ramírez-Bello
SJSILVIA JIMENEZ-MORALES
SILVIA JIMENEZ-MORALES
Acute leukemia (AL) is the main type of cancer in children worldwide. Mortality by this disease is high in developing countries and its etiology remains unanswered. Evidences showing the role of the long non-coding RNAs (lncRNAs) in the pathophysiology of hematological malignancies have increased drastically in the last decade. In addition to the contribution of these lncRNAs in leukemogenesis, recent studies have suggested that lncRNAs could be used as biomarkers in the diagnosis, prognosis, and therapeutic response in leukemia patients. The focus of this review is to describe the functional classification, biogenesis, and the role of lncRNAs in leukemogenesis, to summarize the evidence about the lncRNAs which are playing a role in AL, and how these genes could be useful as potential therapeutic targets.

1 January 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
CBCarolina Bekker-Mendez
Carolina Bekker-Mendez
EMEnrique Miranda-Peralta
Enrique Miranda-Peralta
Juan Carlos Núñez-EnríquezJuan Carlos Núñez-Enríquez
Juan Carlos Núñez-Enríquez
IOIrma Olarte-Carrillo
Irma Olarte-Carrillo
FGFrancisco Xavier Guerra-Castillo
Francisco Xavier Guerra-Castillo
JUAN MANUEL MEJIA-ARANGUREJUAN MANUEL MEJIA-ARANGURE
JUAN MANUEL MEJIA-ARANGURE
Mexico has one of the highest incidences of childhood leukemia worldwide and significantly higher mortality rates for this disease compared with other countries. One possible cause is the high prevalence of gene rearrangements associated with the etiology or with a poor prognosis of childhood acute lymphoblastic leukemia (ALL). The aims of this multicenter study were to determine the prevalence of the four most common gene rearrangements [ETV6-RUNX1, TCF3-PBX1, BCR-ABL1, andMLLrearrangements] and to explore their relationship with mortality rates during the first year of treatment in ALL children from Mexico City. Patients were recruited from eight public hospitals during 2010–2012. A total of 282 bone marrow samples were obtained at each child’s diagnosis for screening by conventional and multiplex reverse transcription polymerase chain reaction to determine the gene rearrangements. Gene rearrangements were detected in 50 (17.7%) patients.ETV6-RUNX1was detected in 21 (7.4%) patients,TCF3-PBX1in 20 (7.1%) patients,BCR-ABL1in 5 (1.8%) patients, andMLLrearrangements in 4 (1.4%) patients. The earliest deaths occurred at months 1, 2, and 3 after diagnosis in patients withMLL, ETV6-RUNX1, andBCR-ABL1gene rearrangements, respectively. Gene rearrangements could be related to the aggressiveness of leukemia observed in Mexican children.

5 August 2016 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
JMJorge Alfonso Martín-Trejo
Jorge Alfonso Martín-Trejo
Juan Carlos Núñez-EnríquezJuan Carlos Núñez-Enríquez
Juan Carlos Núñez-Enríquez
AFArturo Fajardo-Gutiérrez
Arturo Fajardo-Gutiérrez
AMAurora Medina-Sansón
Aurora Medina-Sansón
JFJanet Flores-Lujano
Janet Flores-Lujano
JUAN MANUEL MEJIA-ARANGUREJUAN MANUEL MEJIA-ARANGURE
JUAN MANUEL MEJIA-ARANGURE
The role of malnutrition at diagnosis as a predictor of early mortality in Mexican leukemia children remains controversial. The objective of present study was to investigate whether malnutrition was a predictor of early mortality during the first year of treatment in Mexican acute lymphoblastic leukemia (ALL) children through the first population-based study. A total of 794 newly diagnosed ALL pediatric patients from public hospitals of Mexico City were enrolled. A multivariate Cox proportional hazards regression model was constructed and adjusted by patient’s age at diagnosis, gender, hospital of treatment, and socioeconomic status. Early mortality was high (12.1%) and malnutrition by different indicators was not associated with mortality at induction phase and at 6th month; a high risk of dying (RR = 2.08; 95% CI: 1.08–4.01) was observed in the group of malnourished children with a high-risk ALL.

1 November 2016 in Archives of Medical Research
Verified
Journal Article
Closed access
Juan Carlos Núñez-EnríquezJuan Carlos Núñez-Enríquez
Juan Carlos Núñez-Enríquez
DBDiego Alberto Bárcenas-López
Diego Alberto Bárcenas-López
AHAlfredo Hidalgo-Miranda
Alfredo Hidalgo-Miranda
EJElva Jiménez-Hernández
Elva Jiménez-Hernández
CBCarolina Bekker-Mendez
Carolina Bekker-Mendez
JUAN MANUEL MEJIA-ARANGUREJUAN MANUEL MEJIA-ARANGURE
JUAN MANUEL MEJIA-ARANGURE

18 July 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Juan Carlos Núñez-EnríquezJuan Carlos Núñez-Enríquez
Juan Carlos Núñez-Enríquez
AGAna Elena Gil-Hernández
Ana Elena Gil-Hernández
EJElva Jiménez-Hernández
Elva Jiménez-Hernández
AFArturo Fajardo-Gutiérrez
Arturo Fajardo-Gutiérrez
AMAurora Medina-Sansón
Aurora Medina-Sansón
JUAN MANUEL MEJIA-ARANGUREJUAN MANUEL MEJIA-ARANGURE
JUAN MANUEL MEJIA-ARANGURE
Mexico City has one of the highest incidences and mortality rates of acute lymphoblastic leukemia (ALL) in the world and a high frequency of early relapses (17%) and early mortality (15%). Otherwise, childhood overweight and obesity are reaching epidemic proportions. They have been associated with poor outcomes in children with ALL. The aim of present study was to identify if overweight and obesity are predictors of early mortality and relapse in Mexican children with ALL. A multicenter cohort study was conducted. ALL children younger than 15 years old were included and followed-up during the first 24 months after diagnosis. Overweight and obesity were classified according World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) criteria. Early mortality and early relapses were the main outcomes. A total of 1070 children were analyzed. Overweight/obesity at diagnosis were predictors of early mortality (WHO: HR = 1.4, 95%CI:1.0–2.0; CDC: HR = 1.6, 95%CI:1.1–2.3). However, no associations between overweight (WHO: HR = 1.5, 95%CI:0.9–2.5; CDC: HR = 1.0; 95% CI:0.6–1.6) and obesity (WHO: HR = 1.5, 95%CI:0.7–3.2; CDC: HR = 1.4; 95%CI:0.9–2.3) with early relapse were observed. Overweight and obese patients embody a subgroup with high risk of dying during leukemia treatment.

13 March 2020 in Genes
Verified
Journal Article
Open access
PDF file
DBDiego Bárcenas-López
Diego Bárcenas-López
Juan Carlos Núñez-EnríquezJuan Carlos Núñez-Enríquez
Juan Carlos Núñez-Enríquez
AHAlfredo Hidalgo-Miranda
Alfredo Hidalgo-Miranda
FBFredy Omar Beltran-anaya
Fredy Omar Beltran-anaya
Didier Ismael May-HauDidier Ismael May-Hau
Didier Ismael May-Hau
SJSILVIA JIMENEZ-MORALES
SILVIA JIMENEZ-MORALES
Evidence showing the role of long non-coding RNAs (lncRNAs) in leukemogenesis have emerged in the last decade. It has been proposed that these genes can be used as diagnosis and/or prognosis biomarkers in childhood acute lymphoblastic leukemia (ALL). To know if lncRNAs are associated with early relapse and early mortality, a microarray-based gene expression analysis in children with B-lineage ALL (B-ALL) was conducted. Cox regression analyses were performed. Hazard ratios (HR) and 95% confidence intervals (95% CI) were calculated. LINC00152 and LINC01013 were among the most differentially expressed genes in patients with early relapse and early mortality. For LINC00152 high expression, the risks of relapse and death were HR: 4.16 (95% CI: 1.46–11.86) and HR: 1.99 (95% CI: 0.66–6.02), respectively; for LINC01013 low expression, the risks of relapse and death were HR: 3.03 (95% CI: 1.14–8.05) and HR: 6.87 (95% CI: 1.50–31.48), respectively. These results were adjusted by NCI risk criteria and chemotherapy regimen. The lncRNA–mRNA co-expression analysis showed that LINC00152 potentially regulates genes involved in cell substrate adhesion and peptidyl–tyrosine autophosphorylation biological processes. The results of the present study point out that LINC00152 could be a potential biomarker of relapse in children with B-ALL.